Abstract
No public abstract is available from the verified source records.
Daniela Pedicino
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Mavacamten in adolescents with obstructive hypertrophic cardiomyopathy
10.1056/nejmoa2601103 · 2026
Hypertrophic cardiomyopathy
10.1056/nejmra2413445 · 2025
Hypertrophic cardiomyopathy: prevalence of disease-specific red flags
10.1093/eurheartj/ehaf026 · 2025
Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland
10.1093/oxfordjournals.aje.a009291 · 1997
Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy
10.1056/nejmoa021332 · 2003
Cardiac myosin inhibitors in the treatment of hypertrophic cardiomyopathy: clinical trials and future challenges
10.3390/biom15081098 · 2025
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s0140-6736(20)31792-x · 2020
Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial
10.1001/jamacardio.2023.3342 · 2023
Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE study, EXPLORER-LTE cohort
10.1016/j.jchf.2023.09.028 · 2024
2023 ESC guidelines for the management of cardiomyopathies
10.1093/eurheartj/ehad194 · 2023
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines
10.1016/j.jacc.2024.02.014 · 2024
Long-term favorable cardiac remodeling in obstructive hypertrophic cardiomyopathy patients treated with mavacamten for up to 128 weeks: insights from the VALOR-HCM trial
10.1016/j.jcmg.2025.07.019 · 2025
Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy
10.1056/nejmoa2505927 · 2025
No additional external references are available.